Sirukumab
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Sirukumab (CNTO 136; Janssen/GlaxoSmithKline) is a human monoclonal antibody interleukin-6 receptor antagonist that is currently in Phase III development for rheumatoid arthritis. Sirukumab is also being investigated as a potential treatment for lupus nephritis.
Analyst Outlook
To date, sirukumab’s (Johnson & Johnson/GlaxoSmithKline) clinical performance has been comparable to that of the first-to-market interleukin (IL)-6 inhibitor Actemra (tocilizumab; Chugai/Roche) and the Phase III candidate sarilumab (Sanofi/Regeneron). Datamonitor Healthcare believes that this lack of differentiation, together with sirukumab’s anticipated late market entry in Q2 2018, will restrict the drug’s patient share, even in light of Janssen’s extensive experience in autoimmune indications. Once approved and launched, sirukumab is expected to be used late in the rheumatoid arthritis (RA) treatment paradigm, targeting non-responders to tumor necrosis factor (TNF) therapy.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 sirukumab : Rheumatoid arthritis
LIST OF FIGURES
7 Figure 1: Sirukumab Phase IIa trial design
8 Figure 2: Sirukumab SWOT analysis in rheumatoid arthritis
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of sirukumab (Johnson &
Johnson/GlaxoSmithKline) for rheumatoid arthritis
10 Figure 4: Datamonitor Healthcare’s drug assessment scores and weightings of sirukumab
(Johnson & Johnson/GlaxoSmithKline) for rheumatoid arthritis
LIST OF TABLES
4 Table 1: Sirukumab (Johnson & Johnson/GlaxoSmithKline) drug profile
5 Table 2: Sirukumab’s Phase III trials in rheumatoid arthritis
7 Table 3: Sirukumab Phase IIa trial data
8 Table 4: Sirukumab Phase IIb trial data
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Actemra 
Sign up to the